AusperBio Secures $37 Million in Series A Financing to Advance AHB-137 Clinical Development for HBV Cure

SAN FRANCISCO, July 14, 2024 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies, with the goal of achieving functional cure…